Immune-mediated myositis

4 trials 3 recruiting MedDRA PT
4 Registered trials
3 Recruiting
3 Unique sponsors
2 Unique IMPs
3 Commercial trials
Drug classes (ATC)
— ATC code not specified 3
L Oncology (ATC L) 1
Mechanism of action (INN-stem analysis)
CAR-T cell therapy 1 substance
JAK inhibitor 1 substance
Phase II: 2 Phase I (Other): 2

Filter these 4 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 4 trials

Phase II

2 trials
  • Novartis Pharma AG Commercial
    RAPCABTAGENE AUTOLEUCEL
    2024-514137-38-00 5 countries 2025 n=45
    Ended
  • Medical University Of Vienna Academic
    UPADACITINIB
    2024-513681-19-00 1 country 2025 n=10
    Recruiting

Phase I (Other)

2 trials
  • Chugai Pharmaceutical Co. Ltd. Commercial
    IMP not specified
    2023-507692-21-00 14 countries 2024 n=87
    Recruiting
  • Chugai Pharmaceutical Co. Ltd. Commercial
    IMP not specified
    2024-511346-39-00 14 countries 2025 n=78
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Chugai Pharmaceutical Co. Ltd. Commercial 2 Phase I (Other) 2
Novartis Pharma AG Commercial 1 Phase II 0
Medical University Of Vienna Academic 1 Phase II 1
New trials by year
2024
1
2025
3
← All indication landscapes